Hebrew University drug trials show 50 percent cure rate in lab mice
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.
As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)’s Faculty of Medicine have developed a new biological drug with a cure rate of 50% for lab mice with acute leukemia.
Leukemia produce a variety (and a high quantity) of proteins that together provide leukemic cells with rapid growth and death protection from chemotherapy.
To date, most of the biological cancer drugs used to treat leukemia target only individual leukemic cell proteins. However, during “targeted therapy” treatments, leukemic cells quickly activate their other proteins to block the drug. The result is drug-resistant leukemic cells which quickly regrow and renew the disease.
However, the new drug developed by Ben-Neriah and his team functions like a cluster bomb. It attacks several leukemic proteins at once, making it difficult for the leukemia cells to activate other proteins that can evade the therapy. Further, this single molecule drug accomplishes the work of three or four separate drugs, reducing cancer patients need to be exposed to several therapies and to deal with their often unbearable side-effects.
Additionally promising, is the new drug’s ability to eradicate leukemia stem cells. This has long been the big challenge in cancer therapy and one of the main reasons that scientists have been unable to cure acute leukemia.
“We were thrilled to see such a dramatic change even after only a single dose of the new drug. Nearly all of the lab mice’s’ leukemia signs disappeared overnight,” shared professor Ben-Neriah.
BioTheryX recently bought the rights to this promising drug from HU’s technology transfer company Yissum. Together with Ben-Neriah’s research team, they are now applying for FDA approval for phase I clinical studies.
Receive an email update when we add a new ACUTE MYELOID LEUKEMIA article.
The Latest on: Acute myeloid leukemia
via Google News
The Latest on: Acute myeloid leukemia
Cancer stem cells get energy from protein, and it's proving to be their Achilles' heel
on November 12, 2018 at 12:44 pm
"In acute myeloid leukemia, we've gotten pretty good at killing the bulk of cancer cells, but a small population of cancer stem cells are uniquely equipped to resist these therapies, and these ... […]
Research brings personalized medicine to treat leukemia one step closer
on November 12, 2018 at 8:03 am
Bone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: Wikipedia Scientists at the University of Birmingham have revealed the roles that different types of ... […]
Combination chemotherapy and immunotherapy effective in Phase II leukemia study
on November 8, 2018 at 8:48 am
A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated an encouraging response rate and overall survival in patients ... […]
The Leukemia & Lymphoma Society (LLS) Fuels the Next Generation of Cancer Research Committing More Than $188 Million in Funding
on November 8, 2018 at 6:01 am
The team is working on different therapies to cure MDS or prevent it from progressing to the more deadly acute myeloid leukemia. The program is highly relevant since the prevalence of MDS is estimated ... […]
First-in-class YEATS inhibitors that show promise for leukemia treatment
on November 7, 2018 at 3:39 am
ENL, a YEATS domain-containing protein, specifically 'reads' a histone mark called acetylation, resulting in the faulty activation of cancer-promoting genes in human acute myeloid leukemia (AML ... […]
Researchers develop first chemical inhibitors for treatment of acute myeloid leukemia
on November 6, 2018 at 11:52 pm
A research team led by Dr. Xiang David Li from the Department of Chemistry at The University of Hong Kong (HKU), in collaboration with scientists from Tsinghua University in China, The Rockefeller Uni... […]
argenx (ARGX) nnounces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with ASH Meeting
on November 1, 2018 at 6:16 am
mAbs 2014; 6 (2):523-532). Cusatuzumab is currently being evaluated in patients with hematological malignancies, including a Phase 1/2 trial in combination with azacitidine in patients with newly diag... […]
Celyad (CYAD) to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH
on November 1, 2018 at 6:10 am
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Celyad (Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T ... […]
Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting
on November 1, 2018 at 6:01 am
Oral presentation highlighting updated THINK study data evaluating CYAD-01 without preconditioning chemotherapy in relapsed or refractory (r/r) acute myeloid leukemia (AML) As of July 2018, three ... […]
via Bing News